In a first for upstart synthetic biology field, Zymergen files for $100M IPO
Editor’s note: Interested in following biopharma’s fast-paced IPO market? You can bookmark our IPO Tracker here.
Five years after the synthetic biology company Zymergen raised $174 million from investors by piquing interest in designer microbes, the company has filed for an IPO.
The company penciled in a $100 million raise, although that figure has become a placeholder over the last year for life sciences companies that have their eyes on much larger troves.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.